Patisiran in hereditary transthyretin-mediated amyloidosis
- PMID: 33212064
- DOI: 10.1016/S1474-4422(20)30397-5
Patisiran in hereditary transthyretin-mediated amyloidosis
Comment on
-
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16. Lancet Neurol. 2021. PMID: 33212063 Clinical Trial.
Similar articles
-
Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.Expert Rev Clin Pharmacol. 2019 Feb;12(2):95-99. doi: 10.1080/17512433.2019.1567326. Epub 2019 Jan 18. Expert Rev Clin Pharmacol. 2019. PMID: 30644768 Review.
-
Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.Amyloid. 2020 Sep;27(3):153-162. doi: 10.1080/13506129.2020.1730790. Epub 2020 Mar 4. Amyloid. 2020. PMID: 32131641 Clinical Trial.
-
Response by Solomon to Letter Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study".Circulation. 2019 Jul 9;140(2):e92-e93. doi: 10.1161/CIRCULATIONAHA.119.040941. Epub 2019 Jul 8. Circulation. 2019. PMID: 31283371 No abstract available.
-
Letter by González-Costello et al Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-mediated Amyloidosis: Analysis of the APOLLO Study".Circulation. 2019 Jul 9;140(2):e90-e91. doi: 10.1161/CIRCULATIONAHA.119.039645. Epub 2019 Jul 8. Circulation. 2019. PMID: 31283374 No abstract available.
-
Transthyretin deposition in familial amyloidotic polyneuropathy.Curr Med Chem. 2012;19(15):2304-11. doi: 10.2174/092986712800269236. Curr Med Chem. 2012. PMID: 22471982 Review.
Cited by
-
The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy.BMC Neurol. 2023 Mar 17;23(1):108. doi: 10.1186/s12883-023-03116-7. BMC Neurol. 2023. PMID: 36932361 Free PMC article. Clinical Trial.
-
Novel vectors and approaches for gene therapy in liver diseases.JHEP Rep. 2021 Apr 30;3(4):100300. doi: 10.1016/j.jhepr.2021.100300. eCollection 2021 Aug. JHEP Rep. 2021. PMID: 34159305 Free PMC article. Review.
-
Efficient mRNA delivery to resting T cells to reverse HIV latency.Nat Commun. 2025 May 29;16(1):4979. doi: 10.1038/s41467-025-60001-2. Nat Commun. 2025. PMID: 40442114 Free PMC article.
-
Progress on RNA-based therapeutics for genetic diseases.Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023 Aug 25;52(4):406-416. doi: 10.3724/zdxbyxb-2023-0190. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 37643975 Free PMC article. Chinese, English.
-
Patisiran in ATTRv amyloidosis with polyneuropathy: "PatisiranItaly" multicenter observational study.J Neurol. 2025 Feb 15;272(3):209. doi: 10.1007/s00415-025-12950-3. J Neurol. 2025. PMID: 39954098 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials